Abstract 11P
Background
Adjuvant treatment has become more personalized in resectable NSCLC. New biomarkers are needed to predict treatment outcomes. In this study, we looked for a broadly applicable biomarker using deep learning on hematoxylin and eosin (H&E) histology. Based on recommendations [Salgado et al., Ann Oncol 2015], we focused on analyzing tumor infiltrating lymphocytes in the stromal (sTILs) and the intratumoral (iTILs) compartment. We assessed TILs fully automated at slide and tumor bulk level, guided by manual annotations of the tumor bulk. We hypothesized high iTIL and sTIL density being associated with improved disease-free survival (DFS) in the total study population.
Methods
In this retrospective cohort study, 106 chemo-naive patients with resectable NSCLC were identified in two cohorts, based on recurrence (n=45, cohort A) versus no recurrence (n=61, cohort B). Whole mount tumor slides were stained with H&E and digitalized. Deep learning models were used to compute tissue masks [J. Spronck et al., PLMR 2023] and for TIL detection [HoverNet, Med Imag Anal. 2019]. Tumor bulk was manually annotated to exclude distant tumor lets. Distribution of iTIL and sTIL densities in cohort A and B were compared using Mann-Whitney U based on absence of normal distribution patterns. DFS was measured by log-rank and cox regression to correct for covariates after a binary distinction based on median TIL densities.
Results
The slide and annotation iTIL density were significantly higher in cohort B versus cohort A (slide: 300 vs 232 TILs/mm2, p=0.007 and annotation: 318 vs 230 TILs/mm2, p=0.013). The slide and annotation sTIL density were also higher in cohort B versus A (slide: 1489 vs 1153 TILs/mm2, p=0.035 and annotation: 1753 vs 1469, p=0.030). DFS was significantly higher in patients with a high slide iTIL density compared to patients with a low slide iTIL density (HR 0.44; 95% CI 0.24 to 0.81; P<0.009). DFS remained significant after correction for age, gender, smoking history co-morbidity and clinical stage, but not for ECOG performance.
Conclusions
The iTIL density detected on slide level could serve as favorable prognostic factor in patients with resectable NSCLC, potentially being a biomarker for adjuvant treatment.
Legal entity responsible for the study
The authors.
Funding
NWO/VIDI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session